(Press-News.org) Today in Bahir Dar, Ethiopia, at the occasion of the Leishmaniasis East Africa Platform meeting, which has gathered some 150 African and international leishmaniasis experts, results of a pharmacovigilance – or large-scale treatment safety and efficacy monitoring – plan, carried out by MSF, DNDi, and national partners in Kenya, Sudan, Uganda, and Ethiopia, were presented to key decision makers in order to boost patient access to treatment of kala-azar with the combination of Sodium Stibogluconate and Paromomycin (SSG&PM) in the region. In this large cohort of patients, treated under normal field conditions, the results confirmed the safety and high rate of efficacy of the combination treatment in the fight against this fatal neglected tropical disease.
Over 3000 patients, nearly half of which children, were treated with SSG&PM in Eastern Africa in order to provide large-scale evidence aimed at ensuring that endemic countries in the region include the treatment in their national guidelines and essential medicines lists, in addition to registering the drugs, all of which to ultimately ensure the drugs are procured and made accessible to all patients, even those in the most remote areas. SSG&PM was recommended by the World Health Organization in 2010 as firstline treatment of kala-azar in Eastern Africa following successful Phase III clinical trials carried out by the LEAP platform, DNDi, and partners.
'The results of this pharmacovigilance plan are unambiguous: we need this treatment to reach kala-azar patients even in the most remote and unstable areas with no exception', said Dr Daniel Argaw Dagne, Leishmaniasis Programme, Department of Control of Neglected Tropical Diseases, WHO. 'We have more than enough data, what we need now is action from control programmes', he added.
The study results show a 95% cure rate in a large group of patients at the end of treatment and very low mortality and failure rates, all of which are comparable to prior clinical trial results. The combination treatment importantly aims to replace the treatment of kala-azar with SSG alone, namely due to toxicity levels and cost of treatment. Without treatment, the disease is fatal, and is prone to frequent outbreaks.
Eastern Africa has one of the world's highest kala-azar disease burdens, second only to the Indian subcontinent, and counts anywhere between 30,000 and 57,000 new cases per year. Healthcare providers addressing the outbreak in South Sudan, which began in 2009 and is currently on the verge of its highest peak, with major operational support by MSF and drug procurement support from WHO, have implemented SSG&PM to treat the majority of cases, despite political instability, population displacements, and a floundering health system. Research conducted in Sudan has proven the effectiveness of the treatment in lowering the impact of kala-azar outbreaks.
'While we continue our collective efforts to identify better, and entirely oral new treatments for visceral leishmaniasis, especially for Africa where the disease is difficult to control, we want to see access to SSG&PM secured today by our governments', said Dr Musa Bashir Musa, Minister of Health, Gedarif State, Sudan.
'We have to ensure the pharmacovigilance plan immediately translates into patient access here in Ethiopia and elsewhere in Eastern Africa', said Heran Gerba, Deputy Director General, Ethiopian Food, Medicine and Health Care Administration and Control Authority (EFMHACA), Ethiopia.
INFORMATION:
About Visceral Leishmaniasis (VL or Kala-Azar)
Visceral leishmaniasis is a neglected tropical disease caused by Leishmania donovani or L. infantum. There are an estimated 300,000 new cases of VL per annum. Fatal if left untreated, the disease kills approximately 40,000 people every year, and 90% of cases occur in Sudan, Ethiopia, Kenya, Bangladesh, India, Nepal, and Brazil. VL is characterized by prolonged fever and splenomegaly. The current VL therapies administered include pentavalent antimonials (sodium stibogluconate and meglumine antimoniate), AmBisome®, miltefosine, and paromomycin.
Press Contact
Renee Olende
Regional Communications Manager
DNDi Africa
+251942382130 (Ethiopian Number)
+254 705 639 909 (Kenyan Number)
rolende@dndi.org
Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa
2014-10-01
ELSE PRESS RELEASES FROM THIS DATE:
Long-acting insulin is safer, more effective for patients with Type 1 diabetes
2014-10-01
TORONTO, Oct. 1, 2014 – Long-acting insulin is safer and more effective than intermediate-acting insulin for patients with Type 1 diabetes, according to new research published in the BMJ.
Researchers looked at once-daily and twice-daily doses of both long- and intermediate-acting insulin, ranking their effectiveness, safety and cost-effectiveness.
"In patients with Type 1 diabetes, we found that long-acting insulin is superior to intermediate-acting insulin when it came to controlling blood sugar, preventing weight gain and treating severe hypoglycemia," said Dr. ...
All directions are not created equal for nanoscale heat sources
2014-10-01
Thermal considerations are rapidly becoming one of the most serious design constraints in microelectronics, especially on submicron scale lengths. A study by researchers from the University of Illinois at Urbana-Champaign has shown that standard thermal models will lead to the wrong answer in a three-dimensional heat-transfer problem if the dimensions of the heating element are on the order of one micron or smaller.
"As materials shrink, the rules governing heat transfer change as well," explained David Cahill, a professor of materials science and engineering at Illinois. ...
Microbes in Central Park soil: If they can make it there, they can make it anywhere
2014-10-01
Soil microbes that thrive in the deserts, rainforests, prairies and forests of the world can also be found living beneath New York City's Central Park, according to a surprising new study led by Colorado State University and the University of Colorado Boulder.
The research team analyzed 596 soil samples collected from across Central Park's 843 acres and discovered a stunning diversity of below-ground life, most of which had never been documented before.
Only 8.5 percent to 16.2 percent of the organisms discovered in the park soils, depending on their type, had been ...
Non-citizens face harsher sentencing than citizens in US criminal courts
2014-10-01
WASHINGTON, DC, September 29, 2014 — Non-Americans in the U.S. federal court system are more likely to be sentenced to prison and for longer terms compared to U.S. citizens, according to a new study.
"Much of the discussion in this area has centered around deportation, but increasing numbers of immigrants are being brought before criminal courts, and little is known about how they are treated once they are in the criminal justice system," said Michael T. Light, an assistant professor of sociology at Purdue University and the lead author of the study. "This is a major ...
Immunotherapy could stop resistance to radiotherapy
2014-10-01
Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment, according to a study published in Cancer Research* today (Wednesday).
The researchers, based at The University of Manchester and funded by MedImmune, the global biologics research and development arm of AstraZeneca, and Cancer Research UK, found that combining the two treatments helped the immune system hunt down and destroy cancer cells that weren't killed by the initial radiotherapy in mice with breast, skin and bowel cancers.
Radiotherapy ...
Is Australia prepared for Ebola?
2014-10-01
Australia needs to be proactive about potential disease outbreaks like Ebola and establish a national centre for disease control.
In an Editorial in the October issue of Australian and New Zealand Journal of Public Health, Allen Cheng from Monash University and Heath Kelly from the Australian National University question Australia's preparation for public health crises.
"Australia would do well to heed the lessons learned in other countries and be proactive in co-ordinating a consistent and outward looking response," the authors said.
"Australia needs a national disease ...
Targeted treatment could halt womb cancer growth
2014-10-01
A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer*.
The scientists, from the Division of Gynaecologic Oncology at Yale School of Medicine funded by the National Institutes of Health, showed that the drug afatinib not only killed off uterine serous cancer cells after stopping their growth but also caused tumours to shrink.
The drug, a type of personalised medicine, attacks faults in the HER2 gene which lie at the heart of the cancer cells. This stops the disease ...
Third of countries struggling to meet the needs of aging population
2014-10-01
People around the world are living longer, but social policies to support their wellbeing in later life are lagging behind in many countries. This is according a new report by HelpAge International, developed in partnership with the University of Southampton.
More than a third of countries are falling significantly behind those at the top of the Global AgeWatch Index. It ranks 96 nations on the basis of the quality of life and social and economic wellbeing of older people (over 60s). The Index can also help governments to identify policies and institutional contexts that ...
Developing countries should enroll medical and nursing students from rural areas
2014-10-01
Nearly one third of medical and nursing students in developing countries may have no intention of working in their own countries after graduation, while less than one fifth of them intend to work in rural areas where they are needed most, according to a new study.
Health workforce shortages have been a major factor driving the current outbreak of Ebola in western Africa. The disease initially spread rapidly in rural parts of three of the world's poorest countries (Guinea, Sierra Leone and Liberia), where health workers are scarcest.
The study, which was published in ...
Minimum alcohol pricing would be up to 50 times more effective than below cost selling ban
2014-10-01
The previous policy of setting a minimum unit price would have had a 40-50 times greater effect, particularly among harmful drinkers, say researchers.
Increasing the price of alcohol has been shown to be effective in reducing both consumption levels and harms, and the UK government has been considering different policy options for price regulation in England and Wales.
In 2010, the government announced a ban on "below cost selling" to target drinks which are currently sold so cheaply that their price is below the cost of the tax (duty and VAT) payable on the product. ...